Castle Biosciences Inc (CSTL): Cash & Equivalents
$116.73M
As of 2025-12-31
$62.12M
As of 2026-06-30
-1.7%
3-year compound annual growth
-22.2%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $116.73M | -2.5% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $119.71M | +21.1% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $98.84M | -19.6% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $122.95M | -62.7% | 2024-02-28, Balance as of period end |
| 2021-12-31 | $329.63M | -19.6% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $409.85M | +314.6% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $98.84M | n/m | 2021-03-11, Balance as of period end |
| 2018-12-31 | $4.48M | n/a | 2020-03-10, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Castle Biosciences Inc (CSTL) | 2025-12-31 | $116.73M | -2.5% |
| Fulgent Genetics, Inc. (FLGT) | 2025-12-31 | $50.19M | -9.0% |
| CareDx, Inc. (CDNA) | 2025-12-31 | $65.43M | -43.0% |
| BillionToOne, Inc. (BLLN) | 2025-12-31 | $495.98M | +159.0% |
| Veracyte, Inc. (VCYT) | 2025-12-31 | $362.58M | +51.7% |
| GRAIL, Inc. (GRAL) | 2025-12-31 | $249.73M | +16.6% |
| Caris Life Sciences, Inc. (CAI) | 2025-12-31 | $796.27M | n/m |
| Guardant Health, Inc. (GH) | 2025-12-31 | $378.20M | -28.0% |
| Biodesix Inc (BDSX) | 2025-12-31 | $18.99M | -27.7% |
Compare CSTL, FLGT, CDNA, BLLN side by side · Screen every company in Services-Medical Laboratories ↗